Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756232 · ClinicalTrials.gov registry record · Early Phase 1
Cholinergic Mechanisms of Attention in Aging
A Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT04756232: Completed Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
NCT04756232 is a Early Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 19 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04756232, a Early Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with SCD compared to those without SCD.
Primary Outcome
Proportion of particiapnts who complete study days as measured by study drug administration on both study visits with drug challenge
Interventions
- DRUG Mecamylamine Challenge
- OTHER Placebo Comparator Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2025-05-01 |
| Phase | Early Phase 1 |
What the finished NCT04756232 record still lists
NCT04756232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Mecamylamine Challenge is the first listed.
NCT04756232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04756232 about?
NCT04756232 is a clinical study titled "Cholinergic Mechanisms of Attention in Aging". This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic funct...
What is the current status of trial NCT04756232?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2022-04-21. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT04756232?
The interventions under investigation include: Mecamylamine Challenge (DRUG), Placebo Comparator Challenge (OTHER).
Who is sponsoring clinical trial NCT04756232?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04756232's enrollment target sits among peer trials
19 1292nd of 2000 higher than 686 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI